Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So it's a very appealing profile |
| So we're excited |
| And I think the point we've been trying to make with people is, going forward, while VX-548, we think, is an incredibly compelling profile and a great alternative to opioids that hasn't really existed, there will still be situations where prescription NSAID is appropriate |
| There's an incredible interest in a non-opioid pain reliever like VX-548 and whether it's in the hospital setting with physicians, with administrators or with the PBMs or with the government, we see tremendous traction at this point |
| We had an arm in abdominoplasty and arm in bunionectomy and then an open trial with a bunch of different pain states to demonstrate effectiveness and there in the results in that arm, were also very, very positive |
| So I think we are seeing tremendous momentum again, given all of the problems associated with the opioid [ph] and all of the shortcomings associated with the profile of opioids |
| And obviously, the company has had tremendous momentum and delivered some very compelling data |
| As David described, vanza has incredibly compelling profile, so does TRIKAFTA |
| We are incredibly excited about the opportunity on VX-548 which is our medicine and has the potential to be the first class of new pain medicine in decades |
| We're very pleased with the profile of VX-548, safety, efficacy and including time to onset |
| David Altshuler So TRIKAFTA is an amazing medicine, as we know, tremendous efficacy over 90% -- approved for over 90% of people in the age groups taken by the majority of people with CF diagnosed in the world today and has not only short-term benefits but has long-term data |
| They've been enthusiastic about the program all along and we're really thrilled with the data that we released |
| And across the board, the reaction has been very positive |
| And so excitement among patients, among physicians at Vertex is honestly very high and we see it as a tremendously large opportunity |
| And so with the potential for the advent of VX-548, we see a tremendous opportunity to both transform the way that pain is treated but also provide a societal benefit, particularly in the U.S |
| We are incredibly excited about this |
| But within that context, the data for VX-548 is actually very encouraging for an oral medicine |
| Yes, listen, we've obviously had tremendous commercial success with our CF medicines |
| We've got ample manufacturing capacity |
| So that's a great opportunity for patients to come back on medicine |
| And with that though, we're excited to kick off 2024, continued execution in CF, successful CASGEVY launch, moving programs to the clinic, including the pain program which you described |
| So there's some economic benefit to the company over time as well |
| But again, for the reasons cited, I think there's a really strong pull for an alternative here and those conversations have been going great so far |
| And payers are enthusiastic as well |
| They're all very promising |
| Excellent |
| We appreciate the opportunity |
| That is a significant market opportunity |
| And needless to say but important to say, the safety profile was very similar, essentially indistinguishable from TRIKAFTA which has a remarkable long-term safety data and also it's once-a-day instead of twice-a-day |
| It's exciting times at Vertex |
| Statement |
|---|
| where the opioid crisis continues to be a significant burden on society |
| It would be helpful, I think that Street expectations are low for the initial launch |
| There was some lightning there, I think |
| I think importantly though, we are unconstrained in other ways |
| One is a sweat chloride less than 60 is below the diagnostic threshold |
| We don't know if it's possible or not because the profile is excellent |
| But nonetheless, some stop from time to time |
| NSAIDs have limited effectiveness; opioids have greater effectiveness but a significant burden of side effects, including the potential for addiction |
Please consider a small donation if you think this website provides you with relevant information